Shares in US biotech firm Baxalta (NYSE: BXLT) soared by more than 10% on the New York stock exchange following unconfirmed reports that Ireland-based global pharma company Shire (LSE: SHP) is preparing a new takeover offer.
If successful, the deal would create one of the world’s leading specialists in rare diseases, with product sales of around $20 billion by 2020 and double-digit percent annual growth sales.
Baxalta, which has a market capitalisation of $22.7 billion, would help complement Shire's growing portfolio of high-priced treatments for rare or 'orphan' diseases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze